Event Date: Monday, February 24 to Monday, February 24, 2014
Location: Rayburn House Office Building, Room 2237, Washington, DC
Program Description: The Food and Drug Administration proposed a rule in early November 2013 that could increase generic drug manufacturers’ exposure to civil liability. In 2011, the United States Supreme Court concluded that it was impossible for generic drug manufacturers to change their labels, thus preempting state law failure-to-warn claims. The proposed rule would change this and allow generic drug manufacturers to update labels on their drugs. With this new power comes new responsibility and potential liability; generic drug manufacturers may no longer be shielded from failure-to-warn tort cases. Join us for a discussion of this new rule and its economic impact.
Research Fellow, American Enterprise Institute and CEO, Matrix Global Advisors
For More Information, Contact:
Assistant Director, Research & Policy